{"gene":"ADCY9","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1998,"finding":"Human ADCY9 (AC9) encodes a widely expressed transmembrane adenylyl cyclase that is stimulated by β-adrenergic receptor activation but is insensitive to forskolin, Ca2+, and somatostatin when expressed in HEK-293 cells; divergence at the C2a/C2b junction results in an alternative C2b amino acid sequence compared to mouse AC9, and unlike mouse AC9, human AC9 activity is unaffected by calcineurin inhibitors.","method":"Heterologous expression in HEK-293 cells, pharmacological assays, cDNA cloning, in situ hybridization","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1-2 — direct in-cell enzymatic characterization with multiple pharmacological probes; original cloning/regulatory characterization paper","pmids":["9628827"],"is_preprint":false},{"year":2008,"finding":"miR-142-3p directly targets AC9 (ADCY9) mRNA to suppress cAMP production in CD4+CD25- T cells; in CD4+CD25+ Treg cells, FOXP3 downregulates miR-142-3p, thereby keeping the AC9/cAMP pathway active and supporting Treg suppressor function.","method":"miRNA target validation, cAMP measurement, FOXP3 knockdown/overexpression, T cell functional assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (target validation, cAMP assay, genetic manipulation), highly cited","pmids":["19098714"],"is_preprint":false},{"year":2013,"finding":"miR-181b directly targets AC9 (ADCY9) 3'UTR to post-transcriptionally downregulate AC9 expression, restricting intracellular cAMP production and promoting cell proliferation while inhibiting apoptosis in cervical cancer cells; AC9 and miR-181b exert opposite effects on these phenotypes.","method":"miRNA target validation, cAMP measurement, cell proliferation and apoptosis assays, gain/loss-of-function experiments","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional phenotype with target validation, single lab","pmids":["24269684"],"is_preprint":false},{"year":2014,"finding":"miR-181a targets the 3'UTR of AC9 (ADCY9) mRNA to decrease AC9 expression, reducing intracellular cAMP levels and thereby inhibiting ATRA-induced differentiation of acute promyelocytic leukemia (APL) cells; AC9 enhances the trans-activity of retinoic acid receptor via cAMP/PKA signaling.","method":"3'UTR luciferase reporter assay, AC9 knockdown (siRNA), cAMP measurement, ATRA-induced differentiation assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter validation plus functional phenotypic rescue, single lab","pmids":["24722286"],"is_preprint":false},{"year":2018,"finding":"The isoform-specific carboxyl-terminal C2b domain of AC9 (ADCY9) acts as an auto-inhibitory motif; deletion of the C2b domain markedly enhances cAMP responses to Gs-coupled receptor activation, and residues 1268-1276 within C2b are critical for this auto-inhibition. Proteolytic cleavage of C2b may govern AC9 activation in cardiac tissue.","method":"Stable overexpression in HEK-293 cells, C2b deletion/mutagenesis, cAMP assay, immunoblotting with domain-specific antibodies","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis plus functional cAMP assay, orthogonal antibody validation","pmids":["30121334"],"is_preprint":false},{"year":2018,"finding":"Adcy9 gene inactivation in mice reduces aortic atherosclerosis by decreasing macrophage accumulation and proliferation in plaques, improving endothelial-dependent vasorelaxation (via nitric oxide, cyclooxygenase, and endothelial-dependent hyperpolarization pathways), and reducing endothelial adhesion of splenocytes; these atheroprotective effects are abolished in CETP-transgenic mice, demonstrating an ADCY9-CETP interaction.","method":"Adcy9 gene-trap mouse knockout, atherosclerosis protocol, vasorelaxation assay, macrophage flow cytometry, splenocyte adhesion assay, telemetry, MRI","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple orthogonal phenotypic readouts, epistasis with CETP transgene","pmids":["29674325"],"is_preprint":false},{"year":2020,"finding":"miR-142-3p targets AC9 (ADCY9) mRNA (validated by luciferase reporter assay) to suppress cAMP levels and downstream AMPK pathway activity in rats with sciatic nerve injury; silencing miR-142-3p relieves neuropathic pain by upregulating AC9/cAMP/AMPK signaling and reducing inflammatory factors.","method":"Double luciferase reporter assay, miRNA mimic/siRNA in CCI rat model, cAMP and AMPK pathway protein measurement, behavioral pain assays","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — luciferase validation and in vivo epistasis, single lab","pmids":["33416140"],"is_preprint":false},{"year":2020,"finding":"Deletion of adcy9 in zebrafish (morphant model) causes cardiac malformation, increased macrophage migration and cardiac apoptosis, and upregulation of mmp9 (matrix metalloproteinase 9), establishing adcy9 as a candidate gene for cardiac abnormalities in Rubinstein-Taybi syndrome.","method":"Zebrafish morpholino knockdown, immunofluorescence, RNA sequencing","journal":"Orphanet journal of rare diseases","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo KD with defined phenotype and transcriptomic characterization, ortholog study","pmids":["32321550"],"is_preprint":false},{"year":2023,"finding":"Adcy9 gene inactivation in mice following myocardial infarction reduces infarct size, pathological LV remodeling, and cardiac dysfunction, associated with preserved myocardial capillary density and increased bone marrow adaptive immune (T and B cell) responses; these benefits are lost in CETP-transgenic Adcy9-inactivated mice.","method":"Adcy9 gene-trap mouse KO, coronary artery ligation MI model, echocardiography, histology, flow cytometry","journal":"The Canadian journal of cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with multiple in vivo readouts, epistasis confirmed with CETP transgene","pmids":["37054880"],"is_preprint":false},{"year":2023,"finding":"Overexpression of ADCY9 suppresses proliferation, invasion, and migration of lung adenocarcinoma cell lines (SPCA1 and A549), establishing a tumor-suppressive role linked to its adenylyl cyclase/cAMP-producing function.","method":"ADCY9 overexpression in LUAD cell lines, cell proliferation, invasion, and migration assays","journal":"Journal of thoracic disease","confidence":"Low","confidence_rationale":"Tier 3 — single overexpression approach, no mechanistic pathway validation beyond phenotype","pmids":["37065546"],"is_preprint":false},{"year":2025,"finding":"The Ile772Met (rs2230739) missense polymorphism in ADCY9 reduces protein function; asthma-related cytokines decrease ADCY9 expression and cAMP levels, impairing airway smooth muscle relaxation and promoting remodeling, while ADCY9 overexpression attenuates remodeling. Critically, overexpression of the Met772 mutant fails to prevent airway smooth muscle remodeling, demonstrating that Ile772 is functionally required.","method":"ADCY9 overexpression (wild-type vs. missense mutant) in airway smooth muscle cells, cAMP measurement, airway remodeling assays, clinical FEV1/FVC data","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with functional rescue/failure in relevant cell type, paired with clinical data","pmids":["40816614"],"is_preprint":false}],"current_model":"ADCY9 encodes a transmembrane adenylyl cyclase that produces cAMP downstream of Gs-coupled (e.g., β-adrenergic) receptor activation; its activity is auto-inhibited by an isoform-specific C2b carboxyl-terminal domain (residues 1268-1276), and its expression is post-transcriptionally suppressed by multiple microRNAs (miR-142-3p, miR-181a/b, miR-210-3p) targeting its 3'UTR, placing it as a regulated source of intracellular cAMP in T cells, cardiac tissue, neurons, and airway smooth muscle, with loss of ADCY9 function protecting against atherosclerosis and post-MI remodeling in a CETP-dependent manner."},"narrative":{"teleology":[{"year":1998,"claim":"Cloning and initial characterization of human ADCY9 established that it is a β-adrenergic-responsive adenylyl cyclase with unique pharmacological properties—insensitivity to forskolin, Ca²⁺, somatostatin, and calcineurin—distinguishing it from all other AC isoforms and raising the question of how its activity is regulated.","evidence":"Heterologous expression in HEK-293 cells with pharmacological profiling and cDNA cloning","pmids":["9628827"],"confidence":"High","gaps":["No structural basis for forskolin insensitivity","Endogenous regulatory partners unidentified","Tissue-specific splice variant function unknown"]},{"year":2008,"claim":"Identification of miR-142-3p as a direct post-transcriptional repressor of ADCY9 in T cells revealed how FOXP3-dependent downregulation of this miRNA keeps the AC9/cAMP axis active in Tregs, providing the first mechanism linking ADCY9 regulation to immune suppression.","evidence":"miRNA target validation, cAMP measurement, FOXP3 knockdown/overexpression in human CD4⁺ T cells","pmids":["19098714"],"confidence":"High","gaps":["Whether ADCY9 is the sole cAMP source mediating Treg suppression","Upstream signals controlling miR-142-3p beyond FOXP3"]},{"year":2013,"claim":"Demonstration that miR-181a and miR-181b independently target ADCY9 3′UTR to reduce cAMP in leukemia and cervical cancer cells extended the miRNA regulatory network beyond T cells, linking ADCY9 suppression to proliferative and anti-apoptotic phenotypes and to impaired ATRA-induced differentiation via cAMP/PKA/RAR signaling.","evidence":"3′UTR luciferase reporters, siRNA knockdown, cAMP assays, and ATRA differentiation assays in APL and cervical cancer cell lines","pmids":["24269684","24722286"],"confidence":"Medium","gaps":["Relative contribution of miR-181a vs. miR-181b in vivo","Whether cAMP/PKA is the only downstream effector in these cancer contexts"]},{"year":2018,"claim":"Mutagenesis of the C2b domain revealed an isoform-specific auto-inhibitory mechanism: residues 1268–1276 within the C-terminal C2b domain restrain cAMP production, and C2b deletion markedly enhances Gs-coupled responses, suggesting proteolytic cleavage as a potential activation switch in cardiac tissue.","evidence":"C2b deletion and point mutagenesis in HEK-293 stable lines with cAMP quantification and domain-specific immunoblotting","pmids":["30121334"],"confidence":"High","gaps":["Identity of the protease cleaving C2b in vivo","Structural mechanism by which C2b restrains catalytic activity","In vivo validation of proteolytic regulation in cardiomyocytes"]},{"year":2018,"claim":"Adcy9 knockout in mice demonstrated that loss of AC9 is atheroprotective—reducing macrophage accumulation, improving endothelial vasorelaxation via NO/COX/EDH pathways—and that these benefits are abolished on a CETP-transgenic background, establishing a genetically defined ADCY9–CETP interaction in cardiovascular disease.","evidence":"Adcy9 gene-trap KO mice on atherogenic diet; vasorelaxation, flow cytometry, splenocyte adhesion, MRI; epistasis with CETP transgene","pmids":["29674325"],"confidence":"High","gaps":["Molecular mechanism of ADCY9–CETP interaction (direct vs. indirect)","Cell-type-specific contribution of ADCY9 to atherosclerosis","Whether human ADCY9 loss-of-function variants recapitulate protection"]},{"year":2020,"claim":"Zebrafish adcy9 knockdown produced cardiac malformation, increased macrophage migration, cardiac apoptosis, and mmp9 upregulation, extending ADCY9's cardiovascular role to heart development and implicating it as a candidate gene for cardiac abnormalities in Rubinstein-Taybi syndrome.","evidence":"Zebrafish morpholino knockdown with immunofluorescence and RNA-seq","pmids":["32321550"],"confidence":"Medium","gaps":["Morpholino off-target effects not fully controlled","Whether ADCY9 mutations are found in Rubinstein-Taybi patients","Mechanism linking cAMP loss to mmp9 induction"]},{"year":2023,"claim":"Post-MI studies confirmed that Adcy9 inactivation reduces infarct size, preserves capillary density, and enhances adaptive immune responses in bone marrow, and that CETP expression again abolishes these benefits, reinforcing the CETP-dependent cardioprotective axis of ADCY9 loss.","evidence":"Adcy9 KO mice with coronary ligation MI model; echocardiography, histology, flow cytometry; CETP-transgenic epistasis","pmids":["37054880"],"confidence":"Medium","gaps":["Whether cardioprotection is mediated by local (cardiomyocyte) or systemic (immune) ADCY9 loss","cAMP dynamics in infarcted tissue not measured directly"]},{"year":2025,"claim":"Functional characterization of the Ile772Met polymorphism (rs2230739) showed that the Met772 variant is a loss-of-function allele that fails to prevent cytokine-driven airway smooth muscle remodeling, directly linking an ADCY9 coding variant to impaired cAMP production and asthma-related airway dysfunction.","evidence":"Wild-type vs. I772M mutant overexpression in airway smooth muscle cells, cAMP assay, airway remodeling readouts, paired with clinical FEV1/FVC data","pmids":["40816614"],"confidence":"Medium","gaps":["Structural basis for loss of function by Ile772Met","Whether pharmacological cAMP supplementation rescues the Met772 phenotype in vivo","Population-level replication of the asthma association"]},{"year":null,"claim":"The molecular mechanism by which CETP reverses the cardiovascular benefits of ADCY9 loss remains unresolved, as does the identity of the protease that cleaves the auto-inhibitory C2b domain in vivo, and no high-resolution structure of full-length AC9 with C2b has been reported.","evidence":"","pmids":[],"confidence":"High","gaps":["ADCY9–CETP mechanistic link unknown","C2b-cleaving protease unidentified","No full-length AC9 structural model including C2b"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0009975","term_label":"cyclase activity","supporting_discovery_ids":[0,4,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4,6,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,5,8]}],"complexes":[],"partners":["CETP","FOXP3"],"other_free_text":[]},"mechanistic_narrative":"ADCY9 encodes a transmembrane adenylyl cyclase (AC9) that generates cAMP in response to Gs-coupled receptor stimulation, functioning as a regulated signaling node in immune cells, cardiac tissue, neurons, and airway smooth muscle. Unlike other adenylyl cyclases, AC9 is insensitive to forskolin, Ca²⁺, and calcineurin inhibitors and is auto-inhibited by its isoform-specific C2b carboxyl-terminal domain, with residues 1268–1276 critical for this restraint; proteolytic removal of C2b markedly enhances cAMP output [PMID:9628827, PMID:30121334]. ADCY9 expression is post-transcriptionally tuned by multiple microRNAs (miR-142-3p, miR-181a/b) whose levels set cAMP tone in regulatory T cells, leukemia differentiation, and neuropathic pain circuits [PMID:19098714, PMID:24722286, PMID:33416140]. Genetic inactivation of Adcy9 in mice is atheroprotective—reducing macrophage plaque accumulation and improving endothelial vasorelaxation—and cardioprotective after myocardial infarction, benefits that are abolished when CETP is co-expressed, revealing a functionally significant ADCY9–CETP interaction axis [PMID:29674325, PMID:37054880]."},"prefetch_data":{"uniprot":{"accession":"O60503","full_name":"Adenylate cyclase type 9","aliases":["ATP pyrophosphate-lyase 9","Adenylate cyclase type IX","ACIX","Adenylyl cyclase 9","AC9"],"length_aa":1353,"mass_kda":150.7,"function":"Adenylyl cyclase that catalyzes the formation of the signaling molecule cAMP in response to activation of G protein-coupled receptors (PubMed:10987815, PubMed:12972952, PubMed:15879435, PubMed:9628827). Contributes to signaling cascades activated by CRH (corticotropin-releasing factor), corticosteroids and beta-adrenergic receptors (PubMed:9628827)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O60503/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADCY9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADCY9","total_profiled":1310},"omim":[{"mim_id":"603302","title":"ADENYLATE CYCLASE 9; ADCY9","url":"https://www.omim.org/entry/603302"},{"mim_id":"155600","title":"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1","url":"https://www.omim.org/entry/155600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":48.5}],"url":"https://www.proteinatlas.org/search/ADCY9"},"hgnc":{"alias_symbol":["AC9"],"prev_symbol":[]},"alphafold":{"accession":"O60503","domains":[{"cath_id":"-","chopping":"99-195_218-310","consensus_level":"medium","plddt":86.0725,"start":99,"end":310},{"cath_id":"3.30.70.1230","chopping":"1049-1248_1263-1281","consensus_level":"medium","plddt":86.0799,"start":1049,"end":1281}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O60503","model_url":"https://alphafold.ebi.ac.uk/files/AF-O60503-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O60503-F1-predicted_aligned_error_v6.png","plddt_mean":70.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADCY9","jax_strain_url":"https://www.jax.org/strain/search?query=ADCY9"},"sequence":{"accession":"O60503","fasta_url":"https://rest.uniprot.org/uniprotkb/O60503.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O60503/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O60503"}},"corpus_meta":[{"pmid":"19098714","id":"PMC_19098714","title":"miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19098714","citation_count":225,"is_preprint":false},{"pmid":"9628827","id":"PMC_9628827","title":"Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9628827","citation_count":88,"is_preprint":false},{"pmid":"24269684","id":"PMC_24269684","title":"miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells.","date":"2013","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/24269684","citation_count":62,"is_preprint":false},{"pmid":"21545619","id":"PMC_21545619","title":"Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy.","date":"2010","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21545619","citation_count":44,"is_preprint":false},{"pmid":"29525816","id":"PMC_29525816","title":"ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.","date":"2018","source":"JAMA cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29525816","citation_count":36,"is_preprint":false},{"pmid":"29674325","id":"PMC_29674325","title":"ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein).","date":"2018","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/29674325","citation_count":33,"is_preprint":false},{"pmid":"31331193","id":"PMC_31331193","title":"Impact of ADCY9 Genotype on Response to Anacetrapib.","date":"2019","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/31331193","citation_count":29,"is_preprint":false},{"pmid":"24722286","id":"PMC_24722286","title":"MicroRNA-181a-mediated downregulation of AC9 protein decreases intracellular cAMP level and inhibits ATRA-induced APL cell differentiation.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24722286","citation_count":24,"is_preprint":false},{"pmid":"11840511","id":"PMC_11840511","title":"Molecular analysis, mutation screening, and association study of adenylate cyclase type 9 gene (ADCY9) in mood disorders.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11840511","citation_count":22,"is_preprint":false},{"pmid":"33416140","id":"PMC_33416140","title":"miR‑142‑3p targets AC9 to regulate sciatic nerve injury‑induced neuropathic pain by regulating the cAMP/AMPK signalling pathway.","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33416140","citation_count":21,"is_preprint":false},{"pmid":"30121334","id":"PMC_30121334","title":"Auto-inhibition of adenylyl cyclase 9 (AC9) by an isoform-specific motif in the carboxyl-terminal region.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30121334","citation_count":20,"is_preprint":false},{"pmid":"35130732","id":"PMC_35130732","title":"Multivalent Interactions Drive the Toxoplasma AC9:AC10:ERK7 Complex To Concentrate ERK7 in the Apical Cap.","date":"2022","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/35130732","citation_count":20,"is_preprint":false},{"pmid":"30710569","id":"PMC_30710569","title":"Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury.","date":"2019","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30710569","citation_count":17,"is_preprint":false},{"pmid":"34988676","id":"PMC_34988676","title":"Upregulated microRNA-210-3p improves sevoflurane-induced protective effect on ventricular remodeling in rats with myocardial infarction by inhibiting ADCY9.","date":"2022","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34988676","citation_count":9,"is_preprint":false},{"pmid":"34609279","id":"PMC_34609279","title":"A sex-specific evolutionary interaction between ADCY9 and CETP.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34609279","citation_count":8,"is_preprint":false},{"pmid":"37065546","id":"PMC_37065546","title":"ADCY9 functions as a novel cancer suppressor gene in lung adenocarcinoma.","date":"2023","source":"Journal of thoracic disease","url":"https://pubmed.ncbi.nlm.nih.gov/37065546","citation_count":6,"is_preprint":false},{"pmid":"32983975","id":"PMC_32983975","title":"A Case-Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32983975","citation_count":6,"is_preprint":false},{"pmid":"32321550","id":"PMC_32321550","title":"Role of the ADCY9 gene in cardiac abnormalities of the Rubinstein-Taybi syndrome.","date":"2020","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32321550","citation_count":6,"is_preprint":false},{"pmid":"34173811","id":"PMC_34173811","title":"Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.","date":"2021","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34173811","citation_count":4,"is_preprint":false},{"pmid":"34683946","id":"PMC_34683946","title":"Association between ADCY9 Gene Polymorphisms and Ritodrine Treatment Outcomes in Patients with Preterm Labor.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34683946","citation_count":3,"is_preprint":false},{"pmid":"39057056","id":"PMC_39057056","title":"ADRB2 and ADCY9 Sequence Variations in Brazilian Asthmatic Patients.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/39057056","citation_count":2,"is_preprint":false},{"pmid":"37423551","id":"PMC_37423551","title":"Anti-Inflammatory and Pro-Resolving Actions of the N-Terminal Peptides Ac2-26, Ac2-12, and Ac9-25 of Annexin A1 on Conjunctival Goblet Cell Function.","date":"2023","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37423551","citation_count":2,"is_preprint":false},{"pmid":"37054880","id":"PMC_37054880","title":"Adcy9 Gene Inactivation Improves Cardiac Function After Myocardial Infarction in Mice.","date":"2023","source":"The Canadian journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37054880","citation_count":1,"is_preprint":false},{"pmid":"37579959","id":"PMC_37579959","title":"The rs2601796 variant in ADCY9 gene is associated with severe asthma and less bronchodilator response.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/37579959","citation_count":0,"is_preprint":false},{"pmid":"40816614","id":"PMC_40816614","title":"An Ile to Met polymorphism in ADCY9 promotes airway obstruction and remodeling in asthma.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40816614","citation_count":0,"is_preprint":false},{"pmid":"36111722","id":"PMC_36111722","title":"[Association of the ADCY9 gene and gene-environmental interaction with the susceptibility to childhood bronchial asthma].","date":"2022","source":"Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36111722","citation_count":0,"is_preprint":false},{"pmid":"41827823","id":"PMC_41827823","title":"ADCY9 Regulates Neural Stem Cells Via Mitofusin-1 to Maintain Planarian (Dugesia japonica) Cephalic Ganglia Regeneration.","date":"2026","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41827823","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.05.07.593069","title":"Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes","date":"2024-05-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.07.593069","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16764,"output_tokens":2728,"usd":0.045606},"stage2":{"model":"claude-opus-4-6","input_tokens":6061,"output_tokens":2440,"usd":0.136958},"total_usd":0.182564,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Human ADCY9 (AC9) encodes a widely expressed transmembrane adenylyl cyclase that is stimulated by β-adrenergic receptor activation but is insensitive to forskolin, Ca2+, and somatostatin when expressed in HEK-293 cells; divergence at the C2a/C2b junction results in an alternative C2b amino acid sequence compared to mouse AC9, and unlike mouse AC9, human AC9 activity is unaffected by calcineurin inhibitors.\",\n      \"method\": \"Heterologous expression in HEK-293 cells, pharmacological assays, cDNA cloning, in situ hybridization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in-cell enzymatic characterization with multiple pharmacological probes; original cloning/regulatory characterization paper\",\n      \"pmids\": [\"9628827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"miR-142-3p directly targets AC9 (ADCY9) mRNA to suppress cAMP production in CD4+CD25- T cells; in CD4+CD25+ Treg cells, FOXP3 downregulates miR-142-3p, thereby keeping the AC9/cAMP pathway active and supporting Treg suppressor function.\",\n      \"method\": \"miRNA target validation, cAMP measurement, FOXP3 knockdown/overexpression, T cell functional assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (target validation, cAMP assay, genetic manipulation), highly cited\",\n      \"pmids\": [\"19098714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-181b directly targets AC9 (ADCY9) 3'UTR to post-transcriptionally downregulate AC9 expression, restricting intracellular cAMP production and promoting cell proliferation while inhibiting apoptosis in cervical cancer cells; AC9 and miR-181b exert opposite effects on these phenotypes.\",\n      \"method\": \"miRNA target validation, cAMP measurement, cell proliferation and apoptosis assays, gain/loss-of-function experiments\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional phenotype with target validation, single lab\",\n      \"pmids\": [\"24269684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-181a targets the 3'UTR of AC9 (ADCY9) mRNA to decrease AC9 expression, reducing intracellular cAMP levels and thereby inhibiting ATRA-induced differentiation of acute promyelocytic leukemia (APL) cells; AC9 enhances the trans-activity of retinoic acid receptor via cAMP/PKA signaling.\",\n      \"method\": \"3'UTR luciferase reporter assay, AC9 knockdown (siRNA), cAMP measurement, ATRA-induced differentiation assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter validation plus functional phenotypic rescue, single lab\",\n      \"pmids\": [\"24722286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The isoform-specific carboxyl-terminal C2b domain of AC9 (ADCY9) acts as an auto-inhibitory motif; deletion of the C2b domain markedly enhances cAMP responses to Gs-coupled receptor activation, and residues 1268-1276 within C2b are critical for this auto-inhibition. Proteolytic cleavage of C2b may govern AC9 activation in cardiac tissue.\",\n      \"method\": \"Stable overexpression in HEK-293 cells, C2b deletion/mutagenesis, cAMP assay, immunoblotting with domain-specific antibodies\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis plus functional cAMP assay, orthogonal antibody validation\",\n      \"pmids\": [\"30121334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Adcy9 gene inactivation in mice reduces aortic atherosclerosis by decreasing macrophage accumulation and proliferation in plaques, improving endothelial-dependent vasorelaxation (via nitric oxide, cyclooxygenase, and endothelial-dependent hyperpolarization pathways), and reducing endothelial adhesion of splenocytes; these atheroprotective effects are abolished in CETP-transgenic mice, demonstrating an ADCY9-CETP interaction.\",\n      \"method\": \"Adcy9 gene-trap mouse knockout, atherosclerosis protocol, vasorelaxation assay, macrophage flow cytometry, splenocyte adhesion assay, telemetry, MRI\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple orthogonal phenotypic readouts, epistasis with CETP transgene\",\n      \"pmids\": [\"29674325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-142-3p targets AC9 (ADCY9) mRNA (validated by luciferase reporter assay) to suppress cAMP levels and downstream AMPK pathway activity in rats with sciatic nerve injury; silencing miR-142-3p relieves neuropathic pain by upregulating AC9/cAMP/AMPK signaling and reducing inflammatory factors.\",\n      \"method\": \"Double luciferase reporter assay, miRNA mimic/siRNA in CCI rat model, cAMP and AMPK pathway protein measurement, behavioral pain assays\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — luciferase validation and in vivo epistasis, single lab\",\n      \"pmids\": [\"33416140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Deletion of adcy9 in zebrafish (morphant model) causes cardiac malformation, increased macrophage migration and cardiac apoptosis, and upregulation of mmp9 (matrix metalloproteinase 9), establishing adcy9 as a candidate gene for cardiac abnormalities in Rubinstein-Taybi syndrome.\",\n      \"method\": \"Zebrafish morpholino knockdown, immunofluorescence, RNA sequencing\",\n      \"journal\": \"Orphanet journal of rare diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KD with defined phenotype and transcriptomic characterization, ortholog study\",\n      \"pmids\": [\"32321550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Adcy9 gene inactivation in mice following myocardial infarction reduces infarct size, pathological LV remodeling, and cardiac dysfunction, associated with preserved myocardial capillary density and increased bone marrow adaptive immune (T and B cell) responses; these benefits are lost in CETP-transgenic Adcy9-inactivated mice.\",\n      \"method\": \"Adcy9 gene-trap mouse KO, coronary artery ligation MI model, echocardiography, histology, flow cytometry\",\n      \"journal\": \"The Canadian journal of cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple in vivo readouts, epistasis confirmed with CETP transgene\",\n      \"pmids\": [\"37054880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Overexpression of ADCY9 suppresses proliferation, invasion, and migration of lung adenocarcinoma cell lines (SPCA1 and A549), establishing a tumor-suppressive role linked to its adenylyl cyclase/cAMP-producing function.\",\n      \"method\": \"ADCY9 overexpression in LUAD cell lines, cell proliferation, invasion, and migration assays\",\n      \"journal\": \"Journal of thoracic disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single overexpression approach, no mechanistic pathway validation beyond phenotype\",\n      \"pmids\": [\"37065546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The Ile772Met (rs2230739) missense polymorphism in ADCY9 reduces protein function; asthma-related cytokines decrease ADCY9 expression and cAMP levels, impairing airway smooth muscle relaxation and promoting remodeling, while ADCY9 overexpression attenuates remodeling. Critically, overexpression of the Met772 mutant fails to prevent airway smooth muscle remodeling, demonstrating that Ile772 is functionally required.\",\n      \"method\": \"ADCY9 overexpression (wild-type vs. missense mutant) in airway smooth muscle cells, cAMP measurement, airway remodeling assays, clinical FEV1/FVC data\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional rescue/failure in relevant cell type, paired with clinical data\",\n      \"pmids\": [\"40816614\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADCY9 encodes a transmembrane adenylyl cyclase that produces cAMP downstream of Gs-coupled (e.g., β-adrenergic) receptor activation; its activity is auto-inhibited by an isoform-specific C2b carboxyl-terminal domain (residues 1268-1276), and its expression is post-transcriptionally suppressed by multiple microRNAs (miR-142-3p, miR-181a/b, miR-210-3p) targeting its 3'UTR, placing it as a regulated source of intracellular cAMP in T cells, cardiac tissue, neurons, and airway smooth muscle, with loss of ADCY9 function protecting against atherosclerosis and post-MI remodeling in a CETP-dependent manner.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADCY9 encodes a transmembrane adenylyl cyclase (AC9) that generates cAMP in response to Gs-coupled receptor stimulation, functioning as a regulated signaling node in immune cells, cardiac tissue, neurons, and airway smooth muscle. Unlike other adenylyl cyclases, AC9 is insensitive to forskolin, Ca²⁺, and calcineurin inhibitors and is auto-inhibited by its isoform-specific C2b carboxyl-terminal domain, with residues 1268–1276 critical for this restraint; proteolytic removal of C2b markedly enhances cAMP output [PMID:9628827, PMID:30121334]. ADCY9 expression is post-transcriptionally tuned by multiple microRNAs (miR-142-3p, miR-181a/b) whose levels set cAMP tone in regulatory T cells, leukemia differentiation, and neuropathic pain circuits [PMID:19098714, PMID:24722286, PMID:33416140]. Genetic inactivation of Adcy9 in mice is atheroprotective—reducing macrophage plaque accumulation and improving endothelial vasorelaxation—and cardioprotective after myocardial infarction, benefits that are abolished when CETP is co-expressed, revealing a functionally significant ADCY9–CETP interaction axis [PMID:29674325, PMID:37054880].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Cloning and initial characterization of human ADCY9 established that it is a β-adrenergic-responsive adenylyl cyclase with unique pharmacological properties—insensitivity to forskolin, Ca²⁺, somatostatin, and calcineurin—distinguishing it from all other AC isoforms and raising the question of how its activity is regulated.\",\n      \"evidence\": \"Heterologous expression in HEK-293 cells with pharmacological profiling and cDNA cloning\",\n      \"pmids\": [\"9628827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for forskolin insensitivity\", \"Endogenous regulatory partners unidentified\", \"Tissue-specific splice variant function unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of miR-142-3p as a direct post-transcriptional repressor of ADCY9 in T cells revealed how FOXP3-dependent downregulation of this miRNA keeps the AC9/cAMP axis active in Tregs, providing the first mechanism linking ADCY9 regulation to immune suppression.\",\n      \"evidence\": \"miRNA target validation, cAMP measurement, FOXP3 knockdown/overexpression in human CD4⁺ T cells\",\n      \"pmids\": [\"19098714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADCY9 is the sole cAMP source mediating Treg suppression\", \"Upstream signals controlling miR-142-3p beyond FOXP3\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that miR-181a and miR-181b independently target ADCY9 3′UTR to reduce cAMP in leukemia and cervical cancer cells extended the miRNA regulatory network beyond T cells, linking ADCY9 suppression to proliferative and anti-apoptotic phenotypes and to impaired ATRA-induced differentiation via cAMP/PKA/RAR signaling.\",\n      \"evidence\": \"3′UTR luciferase reporters, siRNA knockdown, cAMP assays, and ATRA differentiation assays in APL and cervical cancer cell lines\",\n      \"pmids\": [\"24269684\", \"24722286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of miR-181a vs. miR-181b in vivo\", \"Whether cAMP/PKA is the only downstream effector in these cancer contexts\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mutagenesis of the C2b domain revealed an isoform-specific auto-inhibitory mechanism: residues 1268–1276 within the C-terminal C2b domain restrain cAMP production, and C2b deletion markedly enhances Gs-coupled responses, suggesting proteolytic cleavage as a potential activation switch in cardiac tissue.\",\n      \"evidence\": \"C2b deletion and point mutagenesis in HEK-293 stable lines with cAMP quantification and domain-specific immunoblotting\",\n      \"pmids\": [\"30121334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protease cleaving C2b in vivo\", \"Structural mechanism by which C2b restrains catalytic activity\", \"In vivo validation of proteolytic regulation in cardiomyocytes\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Adcy9 knockout in mice demonstrated that loss of AC9 is atheroprotective—reducing macrophage accumulation, improving endothelial vasorelaxation via NO/COX/EDH pathways—and that these benefits are abolished on a CETP-transgenic background, establishing a genetically defined ADCY9–CETP interaction in cardiovascular disease.\",\n      \"evidence\": \"Adcy9 gene-trap KO mice on atherogenic diet; vasorelaxation, flow cytometry, splenocyte adhesion, MRI; epistasis with CETP transgene\",\n      \"pmids\": [\"29674325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of ADCY9–CETP interaction (direct vs. indirect)\", \"Cell-type-specific contribution of ADCY9 to atherosclerosis\", \"Whether human ADCY9 loss-of-function variants recapitulate protection\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Zebrafish adcy9 knockdown produced cardiac malformation, increased macrophage migration, cardiac apoptosis, and mmp9 upregulation, extending ADCY9's cardiovascular role to heart development and implicating it as a candidate gene for cardiac abnormalities in Rubinstein-Taybi syndrome.\",\n      \"evidence\": \"Zebrafish morpholino knockdown with immunofluorescence and RNA-seq\",\n      \"pmids\": [\"32321550\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino off-target effects not fully controlled\", \"Whether ADCY9 mutations are found in Rubinstein-Taybi patients\", \"Mechanism linking cAMP loss to mmp9 induction\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-MI studies confirmed that Adcy9 inactivation reduces infarct size, preserves capillary density, and enhances adaptive immune responses in bone marrow, and that CETP expression again abolishes these benefits, reinforcing the CETP-dependent cardioprotective axis of ADCY9 loss.\",\n      \"evidence\": \"Adcy9 KO mice with coronary ligation MI model; echocardiography, histology, flow cytometry; CETP-transgenic epistasis\",\n      \"pmids\": [\"37054880\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether cardioprotection is mediated by local (cardiomyocyte) or systemic (immune) ADCY9 loss\", \"cAMP dynamics in infarcted tissue not measured directly\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Functional characterization of the Ile772Met polymorphism (rs2230739) showed that the Met772 variant is a loss-of-function allele that fails to prevent cytokine-driven airway smooth muscle remodeling, directly linking an ADCY9 coding variant to impaired cAMP production and asthma-related airway dysfunction.\",\n      \"evidence\": \"Wild-type vs. I772M mutant overexpression in airway smooth muscle cells, cAMP assay, airway remodeling readouts, paired with clinical FEV1/FVC data\",\n      \"pmids\": [\"40816614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for loss of function by Ile772Met\", \"Whether pharmacological cAMP supplementation rescues the Met772 phenotype in vivo\", \"Population-level replication of the asthma association\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanism by which CETP reverses the cardiovascular benefits of ADCY9 loss remains unresolved, as does the identity of the protease that cleaves the auto-inhibitory C2b domain in vivo, and no high-resolution structure of full-length AC9 with C2b has been reported.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADCY9–CETP mechanistic link unknown\", \"C2b-cleaving protease unidentified\", \"No full-length AC9 structural model including C2b\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [0, 4, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 6, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 5, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CETP\",\n      \"FOXP3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}